An International, multicenter, randomized clinical study of efficacy, safety, and optimal dosage selection of VM-1500 versus Efavirenz within the background of standard basic antiretroviral therapy, consisting of two nucleoside/nucleotide reverse transcriptase inhibitors, in HIV-1 infected treatment-naïve patients
Latest Information Update: 30 Aug 2018
At a glance
- Drugs Elsulfavirine (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2018 96-Week results presented at the 22nd International AIDS Conference
- 19 Apr 2017 New trial record